CTOs on the Move

Syntimmune

www.syntimmune.com

 
Syntimmune approaches areas of high unmet medical need in a unique way. Instead of searching for novel, unproven disease biology, Syntimmune focuses on areas of science that are well understood and extensively researched. We seek new treatments that build on these areas of scientific consensus and broad applicability. In the case of our lead drug candidate, SYNT001, both the cellular pathway and the specific molecular target have been studied extensively for more than 25 years, spearheaded by the groundbreaking research of the scientific team behind Syntimmune. Building on proven areas of science enables Syntimmune to advance its drug candidates swiftly and predictably. The ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.syntimmune.com
  • 271 Waverley Oaks Road Suite 104
    Waltham, MA USA 02452
  • Phone: 212.498.0011

Executives

Name Title Contact Details

Funding

Syntimmune raised $26M on 03/22/2016
Syntimmune raised $50M on 06/21/2017

Similar Companies

Molecular Toxicology

Molecular Toxicology is a Boone, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ATAI Life Sciences

Bridging the gap between what the #mentalhealth system can provide and what people need. Interested in #psychedelics, #drugdevelopment, and #AI. CEO @FloBrand.

Tessera Therapeutics

Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Forge Therapeutics Inc

Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. Forge has developed a fundamentally new approach for the discovery of metalloprotein inhibitors by focusing first on the metal in the enzyme active site.

Discovery Genomics

Discovery Genomics is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.